Back To Normal? US FDA Schedules In-Person Meeting But Pauses Non-COVID Guidance Development

As the agency and country plot the steps to reopening, a full resumption of activities still seems a long way off.

Compass and keyboard
FDA's recent actions seem to be aiming at different points on the compass as it assesses how the pandemic is affecting operations.

Those in the pharma industry looking for any sign that we soon will be returning to normal life may have been encouraged by a recent Federal Register notice from the US Food and Drug Administration.

The agency announced a meeting on modernizing its data strategy was rescheduled for 30 June and will be held in-person...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from US FDA

More from Agency Leadership